IL-27 alleviates high-fat diet-induced obesity and metabolic disorders by inhibiting adipogenesis via activating HDAC6 March 19, 2025 / IL-27 Obesity Therapy / Metabolic disorder Treatment / HDAC6 Activation Interleukin-27 (IL-27) inhibits adipogenesis and improves metabolic health in high-fat diet-induced obesity...

Rivus Pharmaceuticals Announces Publication of Phase 2a HuMAIN Trial of HU6 in Patients with Obesity-Related Heart Failure in JAMA Cardiology March 12, 2025 / HU6 Obesity Treatment / Heart Failure / Visceral Fat Reduction / Cardiometabolic Disease Therapy / Clinical...

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases March 6, 2025 / RNAi Obesity Treatment / Arrowhead Pharmaceuticals / Metabolic Disease Therapy / Obesity Clinical Trials Arrowhead Pharmaceuticals advances two RNAi-based obesity therapeutics, ARO-INHBE and...

The hidden link between kidney stone disease and obesity February 28, 2025 / Obesity / Kidney Stones / Metabolic Health / Fatty Liver Disease Obesity significantly increases kidney stone risk, particularly calcium oxalate and uric acid stones, due to metabolic...